Conditions: Diabetes Mellitus, Type 1
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: no

Brief summary:
This study involves taking a single dose of 100 milligrams (mg) or 300 mg LY2409021 or placebo (an inactive medicine) taken as up to 3 capsules by mouth. The study will evaluate if this drug will reduce the amount of insulin a type 1 diabetic needs over 24 hours. This study includes a 7-day hospitalization period at the clinical research unit (CRU) and will involve screening within 30 days of the start of the study as well as telephone consultations within 5 days after discharge from the CRU.

Detailed description:

Arms:
arm 1: LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.

Placebo: 2 capsules, administered as a single oral dose on Day 2.

Glucagon: 1 mg administered via intramuscular injection on Day 3. arm 2: LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.

Glucagon: 1 mg administered via intramuscular injection on Day 3. arm 3: Placebo: 3 capsules administered as a single oral dose on Day 2.

Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3.

Interventions: intervention 1: LY2409021 intervention 2: Placebo intervention 3: Glucagon
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered via intramuscular injection

Protocol document: